The anti-cancer drug sector is strong, with Changshan Pharmaceutical leading the gains.

MaticHoleFiller · 2026-04-11T04:38:10+00:00

April 2 News, as of 10:45, the anti-cancer drug sector performed strongly, with Yibai Pharmaceutical and Peking University Medical rising to the daily limit, and others like Changshan Pharmaceutical and Yuheng Pharmaceutical also showing significant gains. Investment should be cautious.

MaticHoleFiller

2026-04-11 04:38:10

Abstract generation in progress

April 2 News: As of 10:45, the oncology drug sector is strong. Yibai Pharmaceutical (rights protection) and Peking University Medical are hitting the daily limit; Changshan Pharmaceutical, Yuheng Pharmaceutical, Guangsheng Tang, Shuanglu Pharmaceutical, Qianqi Pharmaceutical (rights protection), Haiwang Bio, Xinlì Tài, and other individual stocks are leading the gains.

Statement: The market has risks, and investment requires caution. This article is automatically published based on a third-party database and does not represent any views from Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are any discrepancies, please refer to the actual announcements. If you have any questions, please contact biz@staff.sina.com.cn.

Massive information and precise insights are all available on Sina Finance APP

Editor: Xiao Lang Express

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.